PROGNOSTIC ROLE OF FUHRMAN GRADE AND VASCULAR ENDOTHELIAL GROWTH FACTOR IN pT1a CLEAR CELL CARCINOMA IN PARTIAL NEPHRECTOMY SPECIMENS

Minardi, Daniele; Lucarini, Guendalina; Mazzucchelli, Roberta; Milanese, Giulio; Natali, D.; Galosi, Andrea Benedetto; Montironi, Rodolfo; Biagini, G.; Muzzonigro, Giovanni

doi:10.1097/01.ju.0000173078.57871.2d

Cited by 79 publications

(60 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Four (8.3%) developed metastatic disease at 24 months. 29 The majority of series that report metastatic disease indicate that there was interval growth in the primary lesion and that most tumors displayed an accelerated growth rate. 7,14,21,23,30,31,32 Therefore, an increased growth rate may be associated with progression to metastatic disease.…”

Section: Outcomes After Long-term Follow-upmentioning

confidence: 99%

Active Surveillance for Renal Cortical Neoplasms

et al. 2010

View full text Add to dashboard Cite

Section: Outcomes After Long-term Follow-upmentioning

confidence: 99%

Active Surveillance for Renal Cortical Neoplasms

et al. 2010

View full text Add to dashboard Cite

“…4,[14][15][16][17][18][19][20][21][22] However, other studies have reported opposite results correlating higher MVD with poorer prognosis, [23][24][25][26][27][28] whereas others have been unable to find a significant prognostic role for MVD. [29][30][31][32][33] The controversy could result from many nonmechanistic factors, including sample size, sampling bias, the different blood vessel markers chosen for immunohistochemical (IHC) characterization, the quality of IHC staining, the methods of vasculature quantification, and the methods of interpretation. However, one other important cause may be that, without differential analysis, blood vessels in CCRCC may be regarded as a single type of vessel having presumably similar functions throughout, which might not accurately reflect the functional diversity of different types of microvessels.…”

Section: Differential Analysis Of Tumor Vasculaturementioning

confidence: 99%

Complexity of tumor vasculature in clear cell renal cell carcinoma

Qian

Huang

Wondergem

et al. 2009

Cancer

View full text Add to dashboard Cite

Clear cell renal cell carcinoma (CCRCC) is a highly vascularized cancer resistant to conventional chemotherapy and radiotherapy. Antiangiogenic therapy has achieved some effectiveness against this unique malignancy. The complexity of the tumor vasculature in CCRCC has led to differences in correlating tumor microvessel density with patient prognosis. The authors' recent findings demonstrated that there were at least 2 major categories of tumor vessels in CCRCC-namely, undifferentiated and differentiated-correlating with patient prognosis in contrasting ways, with higher undifferentiated vessel density indicating poorer prognosis, and higher differentiated vessel density correlating with better prognosis. Furthermore, the presence of pericytes supporting the differentiated vessels varied in CCRCC. The distributions of pericyte coverage and differentiated vessels in CCRCC were uneven. The tumor margin had a higher pericyte coverage rate for differentiated vessels than did the inner tumor area. The uneven distributions of pericyte coverage and differentiated vessels in CCRCC prompted the authors to revisit the mechanism of tumor central necrosis, which was also known to be a prognostic indicator for CCRCC. The discrepancy of prognostic correlation between protein and messenger RNA levels of vascular endothelial growth factor in CCRCC was discussed. The complexity of the tumor vasculature in CCRCC also led the authors to begin to re-evaluate the therapeutic effects of antiangiogenic agents for each type of tumor vessel, which will in turn significantly broaden understanding of tumor angiogenesis and improve therapeutic effect. Clear cell renal cell carcinoma (CCRCC) is a highly vascularized malignancy. As evaluated by 2-phase multidetector computed tomography angiography, CCRCC is found to be able to develop an aberrant capsular vascular supply with outflow through an ovarian vein or testicular vein, 1 although positron emission tomography shows that blood perfusion of the tumor is reduced compared with normal kidney tissues. 2 Our expression profiling study also indicated that the expression level of vascular endothelial growth factor (VEGF; a potent proangiogenesis factor) in CCRCC is 5-fold higher than in other types of kidney

show abstract

“…remaining 42 articles were reviewed, and of these 23 were excluded, the reasons for which are shown in Figure 1. Thus, 19 studies were included in the quantitative synthesis [10,[19][20][21][22][23][24][25][26][27][28][29][30][31][32][33][34][35][36]. Five of these studies [20,22,25,33,36] did not provide data (HR or Kaplan-Meier curve) to calculate the HR for OS, PFS, or DSS, and therefore could not be included in the meta-analysis.…”

Section: Resultsmentioning

confidence: 99%

“…Analysis of the four studies that provided tumor VEGF expression data [27,29,31,35] indicated that high VEGF expression was associated with worse DSS (pooled HR = 1.83; 95% CI: 1.24 to 2.71; p = 0.003, Figure 2B). …”

Section: Vegf Tumor Expressionmentioning

confidence: 99%

The prognostic value of vascular endothelial growth factor in patients with renal cell carcinoma: a systematic review of the literature and meta-analysis

Shen

Liu

et al. 2017

CIM

View full text Add to dashboard Cite

Objective: Vascular endothelial growth factor (VEGF) serum level or tumor expression may be prognostic in renal cell carcinoma (RCC). The purpose of this meta-analysis was to examine the prognostic value of serum VEGF level and tumor expression in patients with RCC.Methods: PubMed and EMBASE databases were searched until September 26, 2016. Prospective and retrospective studies of RCC patients that had VEGF levels measured were included. Outcome measures were overall survival (OS), disease-specific survival (DSS), and progression-free survival (PFS).Results: A total of 14 studies were included in the meta-analysis. In patients with RCC, elevated serum VEGF level was not associated with OS (pooled hazard ratio [HR] = 1.16; 95% confidence interval [CI]: 0.52 to 2.60; p = 0.716), but was associated with poor DSS (pooled HR = 4.22; 95% CI: 2.02 to 8.79; p < 0.001) and PFS (pooled HR = 1.50; 95% CI: 1.22 to 1.85; p < 0.001). Removal of one study, however, resulted in elevated serum level being associated with poorer OS. Tumor VEGF expression was not associated with OS (pooled HR = 1.48; 95% CI: 0.74 to 2.95; p = 0.263), but was associated with worse DSS (pooled HR = 1.83; 95% CI: 1.24 to 2.71; p = 0.003). Conclusion:In patients with RCC, elevated serum VEGF level is associated with worse OS, DSS, and PFS, while tumor expression is only associated with worse DSS. The number of studies, however, was limited and the results should be interpreted with caution.

show abstract

PROGNOSTIC ROLE OF FUHRMAN GRADE AND VASCULAR ENDOTHELIAL GROWTH FACTOR IN pT1a CLEAR CELL CARCINOMA IN PARTIAL NEPHRECTOMY SPECIMENS

Cited by 79 publications

References 18 publications

Active Surveillance for Renal Cortical Neoplasms

Active Surveillance for Renal Cortical Neoplasms

Complexity of tumor vasculature in clear cell renal cell carcinoma

The prognostic value of vascular endothelial growth factor in patients with renal cell carcinoma: a systematic review of the literature and meta-analysis

Contact Info

Product

Resources

About